Botulinum toxin for amelioration of knee contracture in Duchenne muscular dystrophy.
An 11-year-old non-ambulant boy with Duchenne muscular dystrophy developed tightness in his left knee flexors, which caused difficulties in standing exercises. Botulinum toxin A (BTX-A) was injected into the medial and lateral hamstring muscles and the range of motion increased by 20 degrees but after 5 months, when the pharmacological effect of BTX-A had vanished, an increase of only 5 degrees in range compared with the initial finding was left. It is concluded that there may be a role for BTX-A in controlling contractures in Duchenne muscular dystrophy.
von Wendt
L O
LO
University of Helsinki, Hospital for Children and Adolescents, Neurology, Finland.
Autti-Rämö
I S
IS
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D007717:Knee / Q000503:physiopathology*; D008297:Male; D009136:Muscular Dystrophies / Q000188:drug therapy* / Q000503:physiopathology*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D016059:Range of Motion, Articular
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A